Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated                     Imaging and Therapies in the Era of Precision Oncology

Marin, José Flávio Gomes; Nunes, Rafael Fernandes; Coutinho, Artur Martins; Zaniboni, Elaine C.; Costa, Larissa Bastos; Barbosa, Felipe de Galiza; Queiroz, Marcelo A.; Cerri, Giovanni Guido; Buchpiguel, Carlos Alberto

doi:10.1148/rg.2020200021

Cited by 95 publications

(60 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the lanthanide contraction, the ionic radii of Tc and Re are comparable, which leads to a similar coordination behaviour and complexation chemistry [12]. Rhenium compounds were classically used as non-radioactive reference for technetium-99m-tracers, or as therapeutic pendant when using rhenium-186/-188 [29][30][31] according to the theranostic concept [32,33]. For this purpose, ligand 4a was reacted with (Et 4 N) 2 [Re(CO) 3 Br 3 ] in methanol (last step in Scheme 2) to yield the desired rhenium complex fac-[Re(CO) 3 4a]Br in 95%.…”

Section: Preparation Of the Non-radioactive Rhenium-reference Compoundsmentioning

confidence: 99%

Strategic Evaluation of the Traceless Staudinger Ligation for Radiolabeling with the Tricarbonyl Core

et al. 2021

View full text Add to dashboard Cite

The traceless Staudinger ligation with its two variants is a powerful biorthogonal conjugation method not only for the connection of biomolecules, but also for the introduction of fluorescence- or radiolabels under mild reaction conditions. Herein, the strategic evaluation of the traceless Staudinger ligation for radiolabeling 99mTc using the fac-[Tc(CO)3]+ core is presented. A convenient and high-yielding three-step synthetic procedure of dipicolylamine-based phosphanols as ligands for the mild radiolabeling was developed. The labeling was accomplished using a tricarbonyl kit and a 99mTc-pertechnetate generator eluate showing 87% radiochemical conversion. The respective rhenium-based, non-radioactive reference compounds were synthesized using (Et4N)2[Re(CO)3Br3] as precursor. All products were analyzed by NMR, MS, and elemental analysis. Additional XRD analyses were performed.

show abstract

Section: Preparation Of the Non-radioactive Rhenium-reference Compoundsmentioning

confidence: 99%

Strategic Evaluation of the Traceless Staudinger Ligation for Radiolabeling with the Tricarbonyl Core

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In addition to diagnostic purposes, the advantages of tumor-targeting have also found their way to anti-cancer therapies and precision therapies, labelled as theranostics [ 211 ]. By substituting the radioisotope of targeted PET-tracer, the same vector molecule can be used for radionuclide treatment.…”

Section: Future Perspectives: Application Of Improved Targeting Strategies Technological Advances and A Theranostic Approachmentioning

confidence: 99%

Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy

Dam

Vuijk

Stibbe

et al. 2021

Cancers

View full text Add to dashboard Cite

Background: Despite recent advances in the multimodal treatment of pancreatic ductal adenocarcinoma (PDAC), overall survival remains poor with a 5-year cumulative survival of approximately 10%. Neoadjuvant (chemo- and/or radio-) therapy is increasingly incorporated in treatment strategies for patients with (borderline) resectable and locally advanced disease. Neoadjuvant therapy aims to improve radical resection rates by reducing tumor mass and (partial) encasement of important vascular structures, as well as eradicating occult micrometastases. Results from recent multicenter clinical trials evaluating this approach demonstrate prolonged survival and increased complete surgical resection rates (R0). Currently, tumor response to neoadjuvant therapy is monitored using computed tomography (CT) following the RECIST 1.1 criteria. Accurate assessment of neoadjuvant treatment response and tumor resectability is considered a major challenge, as current conventional imaging modalities provide limited accuracy and specificity for discrimination between necrosis, fibrosis, and remaining vital tumor tissue. As a consequence, resections with tumor-positive margins and subsequent early locoregional tumor recurrences are observed in a substantial number of patients following surgical resection with curative intent. Of these patients, up to 80% are diagnosed with recurrent disease after a median disease-free interval of merely 8 months. These numbers underline the urgent need to improve imaging modalities for more accurate assessment of therapy response and subsequent re-staging of disease, thereby aiming to optimize individual patient’s treatment strategy. In cases of curative intent resection, additional intra-operative real-time guidance could aid surgeons during complex procedures and potentially reduce the rate of incomplete resections and early (locoregional) tumor recurrences. In recent years intraoperative imaging in cancer has made a shift towards tumor-specific molecular targeting. Several important molecular targets have been identified that show overexpression in PDAC, for example: CA19.9, CEA, EGFR, VEGFR/VEGF-A, uPA/uPAR, and various integrins. Tumor-targeted PET/CT combined with intraoperative fluorescence imaging, could provide valuable information for tumor detection and staging, therapy response evaluation with re-staging of disease and intraoperative guidance during surgical resection of PDAC. Methods: A literature search in the PubMed database and (inter)national trial registers was conducted, focusing on studies published over the last 15 years. Data and information of eligible articles regarding PET/CT as well as fluorescence imaging in PDAC were reviewed. Areas covered: This review covers the current strategies, obstacles, challenges, and developments in targeted tumor imaging, focusing on the feasibility and value of PET/CT and fluorescence imaging for integration in the work-up and treatment of PDAC. An overview is given of identified targets and their characteristics, as well as the available literature of conducted and ongoing clinical and preclinical trials evaluating PDAC-targeted nuclear and fluorescent tracers.

show abstract

“…Various novel molecular radioactive biomarkers and therapeutic agents have generated hope for advanced-stage cancer patients. 8…”

Section: Usage Patterns and Trends In Radiation Medicinementioning

confidence: 99%

“…We have witnessed the rapid emerging development of theranostics agents (combination of diagnostic and therapeutic) for precision medicine. Various novel molecular radioactive biomarkers and therapeutic agents have generated hope for advanced‐stage cancer patients 8 …”

Section: Usage Patterns and Trends In Radiation Medicinementioning

confidence: 99%

The status of radiation protection in medicine in the Asia‐Pacific region

Brady

et al. 2021

J Med Imag Rad Onc

View full text Add to dashboard Cite

More than half of the world's population live in Asia-Pacific. This region is culturally diverse, with significant disparities in terms of socio-economic status, provision of health care and access to advanced technology. The medical use of ionising radiation is increasing worldwide and similarly within the Asia-Pacific region. In this paper, we highlight the current status in usage of ionising radiation in medicine in the region, and review the legal framework, implementation and activities in radiation protection. Asia-Pacific countries are active in strengthening radiation protection by promoting education and training. Various projects and activities initiated by international organisations such as the IAEA, WHO and ICRP have provided stimulation in the region, but more work is needed to continue to improve protection practices.

show abstract

Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology

Cited by 95 publications

References 93 publications

Strategic Evaluation of the Traceless Staudinger Ligation for Radiolabeling with the Tricarbonyl Core

Strategic Evaluation of the Traceless Staudinger Ligation for Radiolabeling with the Tricarbonyl Core

Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy

The status of radiation protection in medicine in the Asia‐Pacific region

Contact Info

Product

Resources

About